Seward Appoints Dan Crothers As Managing Director

Worthing, UK – 19th January 2015 – Seward Ltd., manufacturer of the world leading range of original Stomacher® paddle blenders and accessories used in sample preparation for microbiological analysis, is pleased to announce the appointment of Dan Crothers as Managing Director to direct strategy and implement a series of new developments within the Company.

Dan, who has worked with Seward since 2008, assumes the new role after success in previous positions, including managing Seward's Singapore operations and latterly as General Manager of Seward in the UK. As Managing Director, he will oversee the plans for further growth of Seward's business globally, including expansion into new markets such as India, and the launch of a number of new products. 2014 saw strong growth for Seward with a 15% increase in revenue in both Europe and North America.

Growth in the US has been spearheaded by the appointment of Gary Ross as CEO of Seward Laboratory Systems Inc., and the opening of new offices in Florida. With this structure in place, Seward is now positioned to further develop its South American market.

"Over the past few years, Dan's understanding of our customers' needs and international experience has contributed greatly to growing the Stomacher brand, as well as the development of our new product lines," said Howard Matthews, outgoing MD and Non-Executive Director of Seward Ltd. "Dan brings both experience and fresh thinking to the MD position and is extremely well qualified to deliver our ambitious company milestones in 2015 and beyond."

Dan added, "I am extremely proud of Seward and Stomacher's long legacy which is synonymous with robustness and quality in sample preparation. I'm particularly looking forward to bringing our quality new products to market; these are exciting times for the company and our customers will see real benefits, not only in our traditional food sector, but also the life science and environmental markets."

For more information on Seward, please visit www.seward.co.uk.

Editors' notes

About Seward Limited - www.seward.co.uk

Seward manufactures the world leading range of Stomacher® paddle blenders and Stomacher® accessories used in sample preparation for microbiological analyses. The company has been manufacturing and developing the world renown and patented Stomacher® Lab Blender for 40 years. The original and still regarded as the best, over 8 million food samples a day are prepared on Stomacher® 400 paddle blender units around the world.

In addition to sample preparation for food safety analyses, within the bioscience market the new developments of the Stomacher® 80 and micro 80 are proving invaluable for safe and efficient sample processing. The Stomacher® 3500 has established itself as the instrument of choice for preparing samples for the new pathogen test protocols requiring jumbo size samples.

The Company is based in Worthing, West Sussex, UK with subsidiaries in the USA and Singapore. All Seward machine products are manufactured within the UK and 1 of its 3 worldwide Stomacher® bag manufacturing operations is also UK-based. This ensures control of quality and price to deliver excellent value to global trading partners and laboratory customers.

Seward Limited continues to develop the product range, now with 3 patents to its credit. Stomacher® is the most highly referenced brand name in food safety and life science sample preparation in scientific publications. The company also assists customers with method development through reference searches and sample evaluations within its own development laboratory.

The original and still the best. The Stomacher® - a Seward product trade name.

Seward contact details:

Europe, Middle East and ROW: +44 (0) 1903 823077; [email protected]
US & Canada: +1 772 621 8220; [email protected]
Asia and Pacific: +65 6519 2283; [email protected] 

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.